BFEC
CDTX

Benjamin F. Edwards & Company’s Cidara Therapeutics CDTX Stock Holding History

Benjamin F. Edwards & Company’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-307
Closed -$23K – 1672
2020
Q2 		$23K Hold
307
– – ﹤0.01% 1075
2020
Q1 		$15K Buy
307
+57
+23% +$3.42K ﹤0.01% 1151
2019
Q4 		$19K Hold
250
– – ﹤0.01% 1248
2019
Q3 		$10K Hold
250
– – ﹤0.01% 1388
2019
Q2 		$8K Buy
+250
New +$10.4K ﹤0.01% 1475

Other funds holding CDTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

Benjamin F. Edwards & Company's CDTX Position: Q3 2020 in Review

Benjamin F. Edwards & Company sold out of Cidara Therapeutics (CDTX) in Q3 2020, closing a stake of 307 shares — an estimated $23K sold.

Benjamin F. Edwards & Company first reported a position in CDTX in Q2 2019 and held it in 5 quarters. The position peaked at $23K in Q2 2020. 66 funds tracked by Wall St. Rank hold CDTX as of Q3 2020.

  • Benjamin F. Edwards & Company reported no remaining Cidara Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Benjamin F. Edwards & Company sold 307 Cidara Therapeutics shares in Q3 2020, an estimated $23K.
  • Benjamin F. Edwards & Company first reported a position in Cidara Therapeutics in Q2 2019 and held it in 5 quarters.
  • Benjamin F. Edwards & Company's Cidara Therapeutics position peaked at $23K in Q2 2020.
  • 66 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q3 2020.

Based on Benjamin F. Edwards & Company's 13F filing for Q3 2020, filed 13 Nov 2020.